April 27, 2015.
Today's Financial Times (FT) reports
that, since the start of last year, pharmaceuticals companies have agreed $462bn of mergers and acquisitions - greater than the gross domestic product of Austria. In a piece entitled "No end in sight to wave of pharma dealmaking", and following the latest advances by Teva to make a bid for Mylan, Andrew Ward asks "What is driving the frenzy?" According to Jeremy Levin, former chief executive of Teva, the most impetus has been financial rather than strategic. For more on this story,
click here
.
Can Data and AI Deliver Whole-Person Health?
July 9th 2024Executives in the life sciences and medical device industries see promise in artificial intelligence (AI) and medical technologies, but must also navigate the changing healthcare ecosystem, varied stakeholder needs, and the impact of AI on market access and commercialization strategies.